Utah is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Avapritinib With Decitabine in Patients With SM-AHN
NCT06327685
Recruiting
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
Register for Updates
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743
Recruiting
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Local Institution - 0035, Murray, Utah
Conditions: Cardiomyopathy, Hypertrophic
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/30/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
NCT06347796
Recruiting
The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: * Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths? * What is the safety of MMAE and conventional open surgery in these patients? Participants will be asked to: * Share their medical history a... Read More
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
06/28/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Chronic Subdural Hematoma
Register for Updates
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729
Recruiting
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a... Read More
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
06/27/2025
Locations: Wasatch Clinical Research, LLC, Salt Lake City, Utah
Conditions: Acute Treatment of Migraine
Register for Updates
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915
Recruiting
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Huntsman Cancer Institute - Univ of Utah Health, Salt Lake City, Utah
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Intermountain Healthcare, Murray, Utah
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100
Recruiting
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Utah Clinical Neurosciences Center, Salt Lake City, Utah
Conditions: Focal Onset Seizures
Register for Updates
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451
Recruiting
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment 3. to collect safety data in this population for up to three years after the last dose of study treatment
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/27/2025
Locations: Allergy Associates of Utah, Sandy, Utah
Conditions: Chronic Spontaneous Urticaria
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: University of Utah Clinical Neurosciences Center, Salt Lake City, Utah
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492
Recruiting
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
06/27/2025
Locations: JBR Clinical Research - CenExel JBR - PPDS, Salt Lake City, Utah
Conditions: Cytomegalovirus
Register for Updates
Healthy Opioid Prescription Engagement
NCT05141266
Recruiting
This study is a randomized controlled trial across 14 community pharmacies to test the efficacy of the Brief Intervention-Medication Therapy Management intervention (BI-MTM). The establishment of the BI-MTM model will result in a major impact for addressing the opioid epidemic, preventing opioid use disorder and overdose, and safeguarding patient health in a novel community-based service setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations
Register for Updates